Breathe Well Live Well
|
Revalesio Presenting RNS60 Data at ACAAI
Drug Discovery & Development ACAAI (American College of Allergy, Asthma and Immunology) is a professional association with more than 5000 members devoted to the specialty of allergy and immunology. In this first in man asthma study, RNS60 demonstrated therapeutic benefit and … |
View full post on asthma – Google News
|
Revalesio to Present Research on the Anti-Inflammatory Effects of RNS60 in Asthma
Genetic Engineering News Revalesio Corporation announced today that research related to the use of RNS60, its novel anti-inflammatory, will be featured in two poster presentations at the Annual Meeting of the American Academy of Allergy Asthma and Immunology (AAAAI) in San … |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: RNS60; Drug: Normal saline (Placebo); Drug: Budesonide (Pulmicort Respules)
Sponsor: Revalesio Corporation
Recruiting – verified September 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days